Kenya has confirmed its second death from Ebola, as health officials in the Democratic Republic of Congo began vaccinating the first participants in a trial for a vaccine against the strain behind the outbreak. Both announcements came on Friday — and underline the biggest gap in the response: there is still no approved vaccine for this form of the virus.
KEY TAKEAWAYS: Kenya confirms a second Ebola death, with all nine cases in one cluster and no sign of community spread. DR Congo’s Tumaini trial is testing whether an existing vaccine protects against the Bundibugyo strain.
Kenya: nine cases, one cluster
Kenya’s Ministry of Health said the latest victim was a 65-year-old woman and a close family member of the first confirmed case. Quarantined before she developed symptoms on October 13, she is the second death among nine confirmed cases; seven patients remain in treatment at two isolation facilities.
The ministry stressed that the outbreak remains confined to a single chain of transmission. “All nine cases remain within one cluster, with no evidence of community spread,” it said. While every case can be traced to a known contact, health teams can focus on isolation and monitoring rather than hunting for unknown chains.
Kenya had recorded no Ebola cases before this outbreak. Its first case was a Kenyan man who had been living in the Democratic Republic of Congo and travelled back through Uganda.
DR Congo: a trial called “hope”
On the same day, the World Health Organization (WHO) said the first participants had been vaccinated in Bunia, capital of Ituri province and the epidemic’s epicentre. The trial is called Tumaini, Swahili for “hope”.
It will first test Ervebo, approved against the more common Zaire strain, for cross-protection against the Bundibugyo strain driving this outbreak. No vaccine has yet been licensed for Bundibugyo — which is why the trial matters: health workers are fighting a strain they cannot vaccinate against.
Tumaini is a single framework that can test several vaccines, using ring vaccination — immunising close contacts of confirmed cases and others at high risk. It will include pregnant women and children aged 12 and over, groups often left out of vaccine studies. Two Bundibugyo-specific vaccines — an adenoviral-vector candidate from the University of Oxford and an mRNA candidate from Moderna — are expected to join shortly, funded by the Coalition for Epidemic Preparedness Innovations (CEPI).
Why it matters
The Democratic Republic of Congo declared its 17th Ebola outbreak in May, and it has become the country’s worst: more than 9,700 cases and more than 4,600 deaths, as reported by Al Jazeera. The WHO has triggered a public health emergency of international concern, its second-highest alert level, and the outbreak has now been reported in four countries — the widest spread of any Ebola outbreak on the continent.
That scale makes the vaccine question decisive. Ring vaccination helped break chains of transmission in earlier outbreaks of the Zaire strain. If Ervebo — or a Bundibugyo-specific candidate — proves effective, health teams gain a tool they have lacked throughout this epidemic. If not, the response keeps depending on contact tracing, isolation and safe burials.
What happens next
Researchers will watch the first participants for safety and immune response, with evidence building case by case as new contacts are vaccinated. Kenyan officials will keep tracing contacts around the existing cluster, and local reports say the country has sought vaccine doses for frontline workers.
The key questions are straightforward: does Kenya’s cluster stay contained, and does Tumaini produce the first evidence of a vaccine that works against Bundibugyo? The answers will shape not only this outbreak, but how the world prepares for the next one. This article will be updated as official information is released.
Sources
- Al Jazeera — “WHO announces start of Ebola vaccine clinical trial in DR Congo” (Oct 24, 2026)
- News Central TV — “Kenya Confirms Second Ebola Death” (Oct 23, 2026)
- Vietnam.vn / Anadolu — “Ebola outbreak in Africa: Kenya records second death, Democratic Republic of Congo tests new vaccine” (Oct 24, 2026)
- MedicalBrief — “DRC Ebola jab trial starts soon, Kenya records second death” (Oct 2026)
